SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

MOSOVICH, Juan H  y  YOUNG, Pablo. Picadura de medusa Olindias sambaquiensis: Análisis de 49 casos. Medicina (B. Aires) [online]. 2012, vol.72, n.5, pp. 380-388. ISSN 0025-7680.

    1. Nimorakiotakis B, Winkel KD. Marine envenomations. Part 1. Jellyfish (Review). Aust Fam Physician 2003; 32: 969-74. [ Links ]

    2. Vera C, Kolbach M, Zegpi MS, Vera F, Lonza JP. Picaduras de medusas: actualización. Rev Med Chil 2004; 132: 233-41. [ Links ]

    3. Bailey P, Little M, Jelinek G, Wilce J. Jellyfish envenoming syndromes: unknown toxic mechanisms and unproven therapies. Med J Aust 2003; 178: 34-7. [ Links ]

    4. En: http://www.perfil.com.ar/ediciones/2012/2/edicion_652/contenidos/noticia_0058.html; consultado el 4/5/2012. [ Links ]

    5. Müller F. Polypen und Quallen von Santa Catharina. Olindias sambaquiensis n.sp. Archiv für Naturgeschichte 1861; 1: 312-9. [ Links ]

    6. Mianzan H, Zamponi M. Estudio bioecológico de Olindias sambaquiensis, Muller 1861 (Limnomedusae, Olindiidae) en el área de Monte Hermoso: factores meteorológicos que favorecen su aparición. Iheringia Sér misc 1988; 2: 63-8. [ Links ]

    7. Macchi GJ, Mianzan H, Christiansen HE, Ramírez F. Hystology of the gonadal cycle of the stinging hydromedusa Olindias sambaquiensis, Muller [1861] at Blanca Bay, Argentina. Bollettino della Societa Adriatica di Scienze 1995; 76: 59-68. [ Links ]

    8. Kokelj F, Mianzan H, Avian M, Burnett JW. Dermatitis due to Olindias sambaquiensis: a case report. Cutis 1993; 51: 339-42. [ Links ]

    9. Burnett JW, Calton GJ. Venomous pelagic coelenterates: Chemistry, toxicology, inmunology and treatment of their stings (Review). Toxicon 1987; 25: 581-602. [ Links ]

    10. Haddad V Jr, da Silveira FL, Cardoso JL, Morandini AC. A report of 49 cases of cnidarian envenoming from southeastern Brazilian coastal waters. Toxicon 2002; 40: 1445-50. [ Links ]

    11. Haddad V Jr, da Silveira FL, Migotto AE. Skin lesions in envenoming by cnidarians (Portuguese man-of-war and jellyfish): etiology and severity of accidents on the Brazilian coast. Rev Inst Med Trop Sao Paulo 2010; 52: 47-50. [ Links ]

    12. Resgalla C, Rosseto AL, Haddad V. Report of an outbreak of sting caused by Olindias sambaquiensis Muller, 1861 (Cnidaria: Hydrozoa) in Southern Brazil. Brazilian Journal of Oceanography 2011; 59: 391-6. [ Links ]

    13. Burnett JW, Calton GJ, Burnett HW. Jellyfish envenomation syndromes (Review). J Am Acad Dermatol 1986; 14: 100-6. [ Links ]

    14. Singletary EM, Rochman AS, Bodmer JC, Holstege CP. Envenomations (Review). Med Clin North Am 2005; 89: 1195-224. [ Links ]

    15. Currie BJ. Snakes, jellyfish and spiders (Review). Adv Exp Med Biol 2008; 609: 43-52. [ Links ]

    16. Wong D, Meiking T, Rosen L, Taplin D, Hogan D, Burnett J. Seabather's eruption. Clinical, histologic, and immunologic features. J Am Acad Dermatol 1994; 30: 399-406. [ Links ]

    17. Greenland P, Hutchinson D, Park T. Irukandji Syndrome: what nurses need to know (Review). Nurs Health Sci 2006; 8: 66-70. [ Links ]

    18. Ottuso PT. Aquatic antagonists: Cubozoan jellyfish (Chironex fleckeri and Carukia barnesi) (Review). Cutis 2010; 85: 133-6. [ Links ]

    19. Auerbach P, Hays J. Erythema nodosum following a jellyfish sting. J Emerg Med 1987; 5: 487-91. [ Links ]

    20. Burke W. Cnidarians and human skin. Dermatologic Therapy 2002; 15: 18-25. [ Links ]

    21. Kokelj F, Stinco G, Avian M, Mianzan H, Burnett JW. Cell-mediated sensitization to jellyfish antigens confirmed by positive patch tests to Olindias sambaquiensis preparations. J Am Acad Dermatol 1995; 33: 307-9. [ Links ]

    22. Finn BC, Young P, Bruetman JE. Takotsubo, discinesia apical transitoria. Presentación de cuatro casos y revisión de la literatura. Medicina (B Aires) 2005; 65: 415-8. [ Links ]

    23. Arnold JJ, Williams PM. Anaphylaxis: recognition and management (Review). Am Fam Physician 2011; 84: 1111-8. [ Links ]

    24. Hartwick RJ, Callanan V, Williamson JAH. Disarming the box jellyfish: nematocyst inhibition in Chironex fleckeri. Med J Aust 1980; 1: 15-20. [ Links ]

    25. Mianzan HW, Fenner PJ, Cornelius PF, Ramírez FC. Vinegar as a disarming agent to prevent further discharge of the nematocysts of the stinging hydromedusa Olindias sambaquiensis. Cutis 2001; 68: 45-8. [ Links ]

    26. Exton D, Fenner P, Williamson J. Cold packs: effective topical analgesia in the treatment of painful stings by Physalia and other jellyfish. Med J Aust 1989; 151: 625-6. [ Links ]

    27. Carrette TJ, Cullen P, Little M, Peiera PL, Seymour JE. Temperature effects on box jellyfish venom: a possible treatment for envenomed patients? Med J Aust 2002; 177: 654-5. [ Links ]

    28. Taylor JG. Treatment of jellyfish stings. Med J Aust 2007; 186: 43. [ Links ]

    29. Loten C, Stokes B, Worsley D, Seymour JE, Jiang S, Isbister GK. A randomized controlled trial of hot water (45°C) immersion versus ice packs for pain relief in bluebottle stings. Med J Aust 2006; 184: 329-33. [ Links ]

    1. Azziz R. PCOS: A diagnostic challenge. Reprod Biomed Online 2004; 6: 644-8. [ Links ]

    2. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002; 174: 1-5. [ Links ]

    3. Franks S. Polycystic ovary syndrome. New Engl J Med 1995; 333: 853- 61. [ Links ]

    4. Azziz R, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? Fertil Steril 2011; 95: 1544-8. [ Links ]

    5. Zegher F, Ibañez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril 2006; 86: 4-5. [ Links ]

    6. Ong KK, Dunger DB. Birth weight, infant growth and insulin resistance. Eur J Endocrinol 2004; 151: 131-9. [ Links ]

    7. Martı-Henneberg C, Vizmanos B. The duration of puberty in girls is related to the timing of its onset. J Pediatr 1997; 131: 618-21. [ Links ]

    8. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255-60. [ Links ]

    9. Hong Y, Yang D, Liu W, et al. Dyslipidemia in relation to body mass index and insulin resistance in Chinese women with polycystic ovary syndrome. J Biol Regul Homeost Agents. 2011; 25: 365-74. [ Links ]

    10. Wild RA. Dyslipidemia in PCOS. Steroids. 2012; 77: 295-9. [ Links ]

    11. Padmanabhan V, Veiga-Lopez A, Abbott DH, et al. Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 2010; 151: 595-605. [ Links ]

    12. Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2009; 16: 224-31. [ Links ]

    13. Wu XY, Li ZL, Wu CY, et al. Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats. Endocr J 2010; 57: 201-9. [ Links ]

    14. Demissie M, Lazic M, Foecking EM, et al. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab 2008; 295: E262-8. [ Links ]

    15. Amalfi S, Velez L, Heber F, et al. Prenatal hyperandrogenization induces metabolic and endocrine alterations which depend on the levels of testosterone. PloS One 2012; 7: e37658. [ Links ]

    16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502. [ Links ]

    17. Corbould A. Chronic testosterone induces delective insuline resistance in subcutaneos adipocytes of women. J Endocrinol 2007; 192: 585-94. [ Links ]

    18. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 80: 495-506. [ Links ]

    19. Rizzo M, Berneis K. Low- density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99: 1-14. [ Links ]

    20. Ibañez L, Valls C, Potau N, et al. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol 2001; 55: 667-72. [ Links ]

    21. Kimm H, Lee SW, Lee HS, et al. Associations between lipid measures and metabolic syndrome, insulin resistance and adiponectin. - Usefulness of lipid ratios in Korean men and women. Circ J 2010; 74: 931-7. [ Links ]

    22. Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr Opin Cardiol 2012; 398: 398-404. [ Links ]

    23. Rizzo M, Longo RA, Guastella E, et al. Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. J Endocrinol Invest 2011; 34: 422-6. [ Links ]

    1. Charles CA, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 1999; 49: 651-61. [ Links ]

    2. Charles CA, Whelan T, Gafni A, Willan A, Farell S. Shared treatment decision making: what does it mean to physicians? J Gen Clin Oncol 2003; 21: 932-6. [ Links ]

    3. Frosch D, Kaplan R. Shared decision-making in clinical medicine: past research and future directions. Am J Prev Med 1999; 17: 285-94. [ Links ]

    4. Stewart MA. Effective physician-patient communication and health outcomes: a review. Can Med Assoc J 1995; 152: 1423-33. [ Links ]

    5. Institute of Medicine. Improving the 21st Century Health-care System. Crossing the Quality Chasm: A New Health-care System for 21st Century. Washington, DC: National Academy Press; 2001. [ Links ]

    6. Levinson W, Kao A, Kuby A, Thisted RA. Not all patients want to participate in decision making. A national study of public preferences. J Gen Intern Med 2005; 20: 531-5. [ Links ]

    7. Murtagh FEM, Thorns A. Evaluation and ethical review of a tool to explore patient preferences for information and involvement in decision-making. J Med Ethics 2006; 32: 311-5. [ Links ]

    8. Roter DL, Hall JA, Auki Y. Physician gender effects in medical communication. A meta-analytic review. JAMA 2002; 288: 756-64. [ Links ]

    9. Fiscelle K, Franks P, Gold M, Clancy C. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA 2000; 283: 2579-84. [ Links ]

    10. Nayfield S, Bongiovanni G, Alcioti M, Fischer R, Bergner L. Statutory requirements for disclosure of breast cancer treatment alternatives. J Natl Cancer Inst 1994; 86: 1202-8. [ Links ]

    11. Nattinger AB, Hoffman R, Shapiro R, Gottlieb M, Goodwin J. The effect of legislative requirements on the use of breast-conserving surgery. N Engl J Med 1996; 335: 1035-40. [ Links ]

    12. NHS Centre for Reviews and Dissemination. Informing, communicating and sharing decisions with people who have cancer. Effect Health Care 2000; 6: 1-8. [ Links ]

    13. McPherson CJ, Higginson U, Hearn J. Effective methods of living information in cancer: a systematic literature review of randomized controlled trials. J Public Health Med 2001; 23: 227-34. [ Links ]

    14. Harris KA. The informational needs of patients with cancer and their families. Cancer Pract 1998; 6: 39-46. [ Links ]

    15. Eagly AH, Johannesen-Schmidt MC, van Ungen ML. Transformational, transactional, and laissez-faire leadership styles: a meta-analysis comparing women and men. Psycol Bull 2003; 129: 569-91. [ Links ]

    16. Elderkin-Thompson V, Waitzin H. Differences in clinical communication by gender. J Gen Intern Med 1999; 14: 112-21. [ Links ]

    17. Pandey S, Hart J, Tiwary S. Women's health and the Internet: understanding emerging trends and implications. Soc Sci Med 2003; 53: 179-92. [ Links ]

    18. Rosen P, Anell A, Hjortsberg C. Patient views on choice and participation in primary health care. Health Policy 2001; 55: 121-8. [ Links ]

    19. Allanan J, Cleary P, Weissman J, Epstein A. The effects of race of patients' preferentes on racial differences in access to renal transplantation. N Engl J Med 1999; 341: 1661-9. [ Links ]

    20. Einbinder L, Schulman K. The effect of race on the referral process for invasive cardiac procedures. Med Care Res Rev 2000; 57: 162-80. [ Links ]

    21. Etchason J, Armour B, Ofli E, et al. Racial and ethnic disparities in health care. JAMA 2001; 285: 883. [ Links ]

    22. Mobeireek AF, Al-Kassimi F, Al-Zahrani K, et al. Information disclosure and decision-making: the Middle East versus the Far East and the West. J Med Ethics 2008; 34: 225-9. [ Links ]

    23. Deber R, Kraetschmer N, Irving J. What role do patients wish to play in treatment decision-making? Arch Intern Med 1996; 156: 1414-20. [ Links ]

    24. Arora N, McHorney C. Patient preferences for medical decision-making: who really wants to participate? Med Care 2000; 38: 325-41. [ Links ]

    1. Wax JR, Lucas FL, Lamont M, Pinette MG, Cartin A, Blackstone J. Maternal and newborn outcomes in planned home birth vs. planned hospital births: a metaanalysis. Am J Obstet Gynecol 2010; 203: 243. [ Links ]

    2. Birthplace in England Collaborative Group. Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England National Prospective Cohort Study. Br Med J 2011; 343:d7400. [ Links ]

    3. Schroeder E, Petrou S, Patel N, et al. Cost effectiveness of alternative planned places of birth in woman at low risk of complications: evidence from the Birthplace in England National Prospective Cohort Study. Br Med J 2012; 344. [ Links ]

    4. Uranga A, Urman J, Lomuto C, et al. Guía para la atención del parto normal en maternidades centradas en la familia. Dirección Nacional de Salud Materno Infantil Ministerio de Salud, Argentina, 2004. [ Links ]

    5. En: http://www.hcdn.gov.ar/proyxml/expediente.asp?fundamentos=sinumexp=7719-D-2010; consultado 5/5/2012. [ Links ]

    6. En: http://www.perfil.com/ediciones/2011/10/edicion_613/contenidos/noticia_0056.html; consultado 15/5/2012. [ Links ]

    1. Borges JL. Funes el memorioso. En: Artificios (1944). Obras completas. Buenos Aires: Emecé, 1974. p 485-90. [ Links ]

    2. Zweig S. Buchmendel (1929). En: Calidoscopio. Traducción castellana de José Fernández Z. Barcelona: Juventud, 2004, p 193-211. [ Links ]

    3. Draaisma D. Why life speeds up as you get older. How memory shapes our past (2001). Translated from the Dutch by Arnold and Erica Pomerans. Cambridge (UK): Cambridge UP, 2004. Chapter 7. The absolute memories of Funes and Sherashevsky. p 61-72. [ Links ]

    4. Quian Quiroga R. Borges y la memoria. Buenos Aires: Sudamericana, 2011. [ Links ]

    5. Hernández R. Pehuajó: Nomenclatura de las calles. Buenos Aires: J.A. Berra, 1896, p 79-89. Biblioteca Nacional de Argentina: TES 3 A 10 4 1 02/41. En: http://www.bn.gov.ar/digitalizaciones/ficha.php?id=142; consultado el 1/1/2012. [ Links ]

    6. Kandel ER. The Molecular Biology of Memory Storage: A Dialog between Genes and Synapses (Nobel Lecture). En: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2000/kandel-lecture.html; consultado el 1/1/2012. [ Links ]

    1. Sívori ML, Sáenz CB, Riva Posse C. Mortalilidad por asma y enfermedad pulmonar obstructiva crónica en Argentina en el período1980-1998. Medicina (B Aires) 2001; 61: 513-21. [ Links ]

    2. Lang A, Carlsen KH, Haaland G, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy 2008; 63: 1054-60. [ Links ]

    3. Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758-66. [ Links ]

    4. Neffen H, Fritscher C, Schacht FC, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica 2005; 17: 191-7. [ Links ]

    5. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-38. [ Links ]

    6. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096-110. [ Links ]

    7. Marcone DN, Ricarte C, Videla C, et al. Rinovirus. Frecuencia en niños con infección respiratoria aguda, no internados. Medicina (B Aires) 2012; 72: 28-32. [ Links ]

    8. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545-54. [ Links ]

    9. Barton CA, McKenzie DP, Walters EH, Abramson MJ. Interactions between psychosocial problems and management of asthma: who is at risk of dying? J Asthma 2005; 42: 249-56. [ Links ]

    10. Fleming L, Wilson N, Regamey N, Bush A. Are inflammatory phenotypes in children with severe asthma stable? Eur Respir J 2007; 30: 483S. [ Links ]

    11. Mauad T, Poon AH, Hamid Q. Pathology, inflammation and cytokines of severe asthma. Eur Respir Mon 2011; 51: 97-106. [ Links ]

    12. Navarro Merino M, Andrés Martín A, Asensio de la Cruz O, García García ML, Liñán Cortes S, Villa Asensi JR. Guía de diagnóstico y tratamiento del asma de difícil control en niños. An Pediatr (Barc) 2009; 71: 548-67. [ Links ]

    14. Konradsen JR, Nordlund B, Lidegran M, et al. Problematic severe asthma: a proposed approach to identifying children who are severely resistant to therapy. Pediatr Allergy Immunol 2011; 22: 9-18. [ Links ]

    15. Lodrup Carlsen KC, Hedlin G, Bush A, et al. Assessment of problematic severe asthma in children. Eur Respir J 2011; 37: 432-40. [ Links ]

    16. Saglani S, Papaioannou G, Khoo L, et al. Can HRCT be used as a marker of airway remodelling in children with difficult asthma? Respir Res 2006; 7: 46. [ Links ]

    17. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119: 817-25. [ Links ]

    18. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-7. [ Links ]

    19. Bossley CJ, Saglani S, Kavanagh C, et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. Eur Respir J 2009; 34: 1052-9. [ Links ]

    20. British Thoracic Society, Scottish Intercollegiate Guidelines Network, British Guideline on the Management of Asthma. Thorax 2008; 63: Suppl. 4, iv1-iv121. [ Links ]

    21. Roncoroni AJ. Relación entre asma, atopía, IgE e hiperreactividad bronquial. Medicina (B Aires) 1998; 58: 243-6. [ Links ]

    22. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27: 615-26. [ Links ]

    23. Langley SJ, Goldthorpe S, Craven M, Woodcock A, Custovic A. Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects. Thorax 2005; 60: 17-21. [ Links ]

    24. Chinn S, Heinrich J, Anto JM, et al. Bronchial responsiveness in atopic adults increases with exposure to cat allergen. Am J Respir Crit Care Med 2007; 176: 20-6. [ Links ]

    25. Bush RK. Indoor allergens, environmental avoidance, and allergic respiratory disease. Allergy Asthma Proc 2008; 29: 575-9. [ Links ]

    26. Gotzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy 2008; 63: 646-59. [ Links ]

    27. de Vries MP, van den Bemt L, Aretz K, et al. House dust mite allergen avoidance and self-management in allergic patients with asthma: randomised controlled trial. Br J Gen Pract 2007; 57: 184-90. [ Links ]

    28. van den Bemt L, de Vries MP, Cloosterman S, et al. Influence of house dust mite impermeable covers on health-related quality of life of adult patients with asthma: results of a randomized clinical trial. J Asthma 2007; 44: 843-8. [ Links ]

    29. McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089-97. [ Links ]

    30. De Boeck K, Moens M, Van Der Aa N, Meersman A, Schuddinck L, Proesmans M. 'Difficult asthma': can symptoms be controlled in a structured environment? Pediatr Pulmonol 2009; 44: 743-8. [ Links ]

    31. Hamouda S, Karila C, Connault T, Scheinmann P, de Blic J. Allergic rhinitis in children with asthma: a questionnaire-based study. Clin Exp Allergy 2008; 38: 761-6. [ Links ]

    32. Kang HY, Park CS, Bang HR, Sazonov V, Kim CJ. Effect of allergic rhinitis on the use and cost of health services by children with asthma. Yonsei Med J 2008; 49: 521-9. [ Links ]

    33. Taramarcaz P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev 2003; 4: CD003570. [ Links ]

    34. James JM. Respiratory manifestations of food allergy. Pediatrics 2003; 111: 1625-30. [ Links ]

    35. Sicherer SH, Furlong TJ, Munoz-Furlong A, Burks AW, Sampson HA. A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149 registrants. J Allergy Clin Immunol 2001; 108: 128-32. [ Links ]

    36. de Groot EP, Duiverman EJ, Brand PL. Comorbidities of asthma during childhood: possibly important, yet poorly studied. Eur Respir J 2010; 36: 671-8. [ Links ]

    37. Kopel SJ, Klein RB. Childhood asthma and obesity. Med Health R I 2008; 91: 161-4. [ Links ]

    38. Scholtens S, Wijga AH, Seidell JC, et al. Overweight and changes in weight status during childhood in relation to asthma symptoms at 8 years of age. J Allergy Clin Immunol 2009; 123:1312-8 e2. [ Links ]

    39. Tolia V, Vandenplas Y. Systematic review: the extra-oesophageal symptoms of gastro-oesophageal reflux disease in children. Aliment Pharmacol Ther 2009; 29: 258-72. [ Links ]

    40. Gustafsson PM, Kjellman NI, Tibbling L. Oesophageal function and symptoms in moderate and severe asthma. Acta Paediatr Scand 1986; 75: 729-36. [ Links ]

    41. Gustafsson PM, Kjellman NI, Tibbling L. Bronchial asthma and acid reflux into the distal and proximal oesophagus. Arch Dis Child 1990; 65: 1255-8. [ Links ]

    42. Kenn K, Balkissoon R. Vocal cord dysfunction: what do we know? Eur Respir J 2011; 37: 194-200. [ Links ]

    43. Strunk RC, Mrazek DA, Fuhrmann GS, LaBrecque JF. Physiologic and psychological characteristics associated with deaths due to asthma in childhood. A case-controlled study. JAMA 1985; 254: 1193-8. [ Links ]

    44. Bergstrom SE, Boman G, Eriksson L, et al. Asthma mortality among Swedish children and young adults, a 10-year study. Respir Med 2008; 102: 1335-41. [ Links ]

    45. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2009. Gig Harbor WA. Medical Communications Resources, Inc., 2009. [ Links ]

    46. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma - Summary Report 2007. J Allergy Clin Immunol 2007; 120:S94-S138. [ Links ]

    47. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246-51. [ Links ]

    48. Thompson J, Irvine T, Grathwohl K, Roth B. Misuse of metered-dose inhalers in hospitalized patients. Chest 1994; 105: 715-7. [ Links ]

    49. Bracken M, Fleming L, Hall P, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child 2009; 94: 780-4. [ Links ]

    50. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35: 408-16. [ Links ]

    51. Chand HS, Schuyler M, Joste N, et al. Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways. J Allergy Clin Immunol 2010; 125: 1157-8 e5. [ Links ]

    52. Oliver JM, Tarleton CA, Gilmartin L, et al. Reduced FcepsilonRI- mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2009; 151: 275-84. [ Links ]

    53. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7: 365-78. [ Links ]

    54. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008; 8: 205-17. [ Links ]

    55. Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010; 125: 896-901 e6. [ Links ]

    56. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16. [ Links ]

    57. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632-8. [ Links ]

    58. Walker S, Monteil M, Phelan K. et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; Apr 19. (2): CD003559. [ Links ]

    59. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-8. [ Links ]

    60. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233-40. [ Links ]

    61. Busse W, Fox H, Surrey K, et al. Relevant improvements in asthma related quality of life in patients receiving omalizumab as add-on therapy. J Allergy Clin Immunol 2006; 117: S8. [ Links ]

    62. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709-17. [ Links ]

    63. Milgrom H, Berger W; Nayak A, et al. Treatment of Childhood Asthma With Anti Immunoglobulin E Antibody (Omalizumab) Pediatrics 2001; 108:2: e36-46. [ Links ]

    64. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124: 1210-6. [ Links ]

    65. Kulus M, Hebert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin 2010; 26: 1285-93. [ Links ]

    66. Fried AJ, Oettgen HC. Anti-IgE in the treatment of allergic disorders in pediatrics. Curr Opin Pediatr 2010; 22: 758-64. [ Links ]

    67. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701-8. [ Links ]

    68. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as addon therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35. [ Links ]

    69. Sullivan SD, Weiss KB, Lynn H, et al. The cost-effectiveness of an inner-city asthma intervention for children. J Allergy Clin Immunol 2002; 110: 576-81. [ Links ]

    70. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. [ Links ]

    1. Arce H. El Sistema de Salud; de dónde viene y hacia dónde va. Buenos Aires: Editorial Prometeo, 2010, p 149-1. [ Links ]

    2. Wagstaff A. Social Health Insurance Reexamined. Development Research Group, World Bank Policy Research Working Paper 4111, Washington D.C., January 2007. [ Links ]

    3. Matta M, Leiva L. Sistemas de salud en el mundo. Buenos Aires: Editorial Dunken, 2008, Tomo I, p 61-103. [ Links ]

    4. Sánchez Rodríguez H. (ed.). La Salud del Bicentenario, Chile 2011-2020. Santiago: Universidad Andrés Bello, 2011. [ Links ]

    5. Arce H. El Sistema de Salud; de dónde viene y hacia dónde va. Buenos Aires: Editorial Prometeo, 2010, p 289-209. [ Links ]

    6. Ministerio de Salud de la Nación: Catastro de Recursos de Salud. Buenos Aires: Editorial MSal, 2000. [ Links ]

    7. Torres R. Mitos y realidades de las Obras Sociales. Buenos Aires: Editorial ISalud, 2004, p 137. [ Links ]

    8. Arce H. La Medicina Prepaga en Argentina. Medicina y Sociedad, Vol. 31, N° 3, Buenos Aires, 2011. En: http://www.medicinaysociedad.org.ar/publicaciones/00_1SEP2011/01sep_2011.html; consultado el 20/9/2011. [ Links ]

    9. Tobar F, Olaviaga S, Solano R. Retos postergados y nuevos desafíos del sistema de salud argentino. CIPPEC, Documento de Políticas Públicas N° 99, Buenos Aires, 2011. [ Links ]

    10. Torres R. Mitos y realidades de las Obras Sociales. Buenos Aires: Editorial ISalud, 2004, p 161-8. [ Links ]

    11. Key Market en base a datos de Ministerios de Economía y Salud, INDEC, ISalud, ACAMI, ADEMP, AFIP, COSSPRA y SSS. En: http://www.ieco.clarin.com/economia/salud-pais-gasta-paga_0_266973529.html; consultado el 23/5/2010. [ Links ]

    1. Lip, GYH, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13: 723-46. [ Links ]

    2. Garcia DA, Lopes RD, Hylek EM. New- onset atrial fibrillation and warfarin initiation; High risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-105. [ Links ]

    3. Fanikos J, Corranti GN, Shah R, et al. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 2005; 96: 595-8. [ Links ]

    4. Palaretti G, Cosmi B. Bleeding with anticoagulation therapy. Who is at risk and how best to identify such patients. Thromb Haemost 2009; 102: 268-78. [ Links ]

    5. Chen WT, White CM, Phung OJ, et al. Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review. Int J Clin Pract 2011; 65: 719-21. [ Links ]

    6. Palaretti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective- collaborative study (ISCOAT) Italian study on complications of oral anticoagulant therapy. Lancet 1996; 348: 423-8. [ Links ]

    7. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52. [ Links ]

    8. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-9. [ Links ]

    9. Kuijer PMM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-60. [ Links ]

    10. Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003; 163: 917-20. [ Links ]

    11. Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med 2005; 20: 1008-13. [ Links ]

    12. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-9. [ Links ]

    13. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130: 1390-6. [ Links ]

    14. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31. [ Links ]

    15. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100. [ Links ]

    16. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011: 90: 1191-200. [ Links ]

    17. Olesen JB, Lip GYH, Hansen PR, et al. Bleeding risk in real world patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9: 1460-7. [ Links ]

    18. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from the SPORTIF III and V. Arch Intern Med 2007; 167: 239-45. [ Links ]

    19. Connelly SJ, Ezekowitz MD, Yusuf S, et al [for the RE-LY Steering Committee and Investigators]. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51. [ Links ]

    20. Patel MR, Mahaffey KW, Garg J, et al [for the ROCKET AF Steering Committee and Investigators]. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91. [ Links ]

    21. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92. [ Links ]

    22. Hylek EM, Evans-Molina C, Shea C, et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients with Atrial Fibrillation. Circulation 2007; 115: 2689-96. [ Links ]

    23. Eikelboom JW, Wallentin L, Connelly SJ, et al. Risk of bleeding with two doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Trial. Circulation 2011; 123: 2363-72. [ Links ]

    24. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of venous thromboembolism. N Engl J Med 2009; 361: 1-11. [ Links ]

    25. The EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510. [ Links ]

    26. Danziger J. Vitamin K-dependent proteins, warfarin and vascular calcification. Clin J Am Soc Nephrol 2008; 3: 1504-10. [ Links ]

    27. Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012; 66: 53-63. [ Links ]

    28. Stuebe AM. Level IV-evidence. Adverse anecdote and clinical practice. N Engl J Med 2011; 365: 8-9. [ Links ]

    1. Dalmau J, Rosenfeld MR, Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-40. [ Links ]

    2. Sethi S, Tageja N, Singh J, et al. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma. Am J Med Sci 2009; 338: 522-4. [ Links ]

    3. Edmonson HA. Differencial diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. Arch Dis Child 1956; 1: 168-86. [ Links ]

    4. Hamilton SR, Aaltonen LA (ed). Tumors of the liver and intrahepatic bile ducts. In: Pathology and genetics of the digestive system. Lyon: IARC Press; 2000, p 159-72. [ Links ]

    5. Stephen C, Ward, MD, Waxman S. Fibrolamellar Carcinoma: A review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011; 31: 61-70. [ Links ]

    6. Craig JR, Peters RL, Edmonson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinic pathologic features. Cancer 1980; 46: 372-9. [ Links ]

    7. Waxman S, Gilbert HS. A tumor-related vitamin B12 binding protein in adolescent hepatoma. N Engl J Med 1973; 289: 1053-6. [ Links ]

    8. Waxman S, Liu CK, Schreiber C, Helson L.The clinical and physiological implications of hepatoma B12-binding proteins. Cancer Res 1977; 37: 1908-14. [ Links ]

    9. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006; 106: 1331-8. [ Links ]

    10. Epstein Be, Pajak TF, Haulk TL, Herpst JM, Order SE, Abrams RA. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol 1999; 22: 22-8. [ Links ]

    1. Maruyama D, Watanabe T, Beppu Y, et al. Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol 2007; 37: 216-23. [ Links ]

    2. LaCasce A, Freedman A, DeLaney T, Connor R. Primary lymphoma of bone. UptoDate. En: http://www.uptodate.com/contents/primary-lymphoma-of-bone; consultado 20/3/2012. [ Links ]

    3. Kitsoulis P, Vlychou M, Papoudou-Bai A, et al. Primary lymphomas of bone. Anticancer Res 2006; 26: 325-37. [ Links ]

    4. Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007; 18: 129-35. [ Links ]

    5. Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106: 2652-6. [ Links ]

    6. Horsman JM, Thomas J, Hough R, Hancock BW. Primary bone lymphoma: a retrospective analysis. Int J Oncol 2006; 28: 1571-5. [ Links ]

    7. Qureshi A, Ali A, Riaz N, Pervez S. Primary non-hodgkin's lymphoma of bone: experience of a decade. Indian J Pathol Microbiol 2010; 53: 267-70. [ Links ]

    8. Heyning FH, Hogendoom PC, Kramer MH, et al. Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 1999; 13: 2094-8. [ Links ]

    9. Ford DR, Willson D, Sothi S, Grimer R, Spooner D. Primary bone lymphoma: treatment and outcome. Clin Oncol (R. Coll Radiol) 2007; 19: 50-5. [ Links ]

    10. Ostrowky ML, Unni KK, Banks PM, et al. Malignant lymphoma of bone. Cancer 1986; 58: 2646-55. [ Links ]

    11. Zinzani PL, Carrillo G, Ascani S, et al. Primary bone lymphoma: experience with 52 patients. Haematologica 2003; 88: 280-5. [ Links ]

    12. Yabe H, Ueno H, Ochi K, Morioka H, Yabe H, Terai C. Possible clinical significance of serum soluble interleukin- 2 receptor level in primary bone lymphoma: two case reports. Case Rep Oncol 2011; 4: 125-31. [ Links ]

    13. Akahane T, Shimizu T, Isobe K, Yoshimura Y, Kato H. Serum soluble interleukin-2 receptor levels in patients with malignant lymphoma of bone. J Orthop Sci 2009; 14: 248-52. [ Links ]

    14. Even-Sapir, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non- Hodgkin lymphoma and Hodgkin's disease. Radiol Clin North Am 2007; 45: 697-709. [ Links ]

    1. A Report from the STS National Database Committee and the Duke Clinical Research Institute. En: www.STS.org; consultado el 03/02/2012. [ Links ]

    2. Lowenstein Haber D, Guardiani F, Pieroni P, et al. Realidad de la cirugía cardíaca en la República Argentina. Registro CONAREC XVI. Rev Argent Cardiol 2010; 78: 228-37. [ Links ]

    3. Remadi JP, Bizouarn P, Baron O, et al. Mitral valve replacement with the St. Jude medical prosthesis: a 15-year follow-up. Ann Thorac Surg 1998; 66: 762-7. [ Links ]

    4. Dávila-Román V, Waggoner A, Kennard E, et al. Prevalence and severity of paravalvular regurgitation in the artificial valve endocarditis reduction trial (AVERT) echocardiography study. J Am Coll Cardiol 2004; 44: 1467-72. [ Links ]

    5. Chen YT, Kan MN, Chen JS, et al. Detection of prosthetic mitral valve leak: a comparative study using transesophageal echocardiography, transthoracic echocardiography, and auscultation. J Clin Ultrasound 1990; 18: 557-61. [ Links ]

    6. Ionescu A, Fraser G, Butchart E. Prevalence and clinical significance of incidental paraprosthetic valvar regurgitation: a prospective study using transoesophageal echocardiography. Heart 2003; 89: 1316-21. [ Links ]

    7. Hammermeister K, Sethi G, Henderson W, Grover F, Oprian C, Rahimtoola S. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the veterans affairs randomized trial. J Am Coll Cardiol 2000; 36: 1152-8. [ Links ]

    8. Genoni M, Franzen D, Tavakoli R, et al. Does the morphology of mitral paravalvular leaks influence symptoms and hemolysis? J Heart Valve Dis 2001; 10: 426-30. [ Links ]

    9. Genoni M, Franzen D, Vogt P, et al. Paravalvular leakage after mitral valve replacement: improved long-term survival with aggressive surgery? Eur J Cardiothorac Surg 2000; 17: 14-9. [ Links ]

    10. Expósito V, García-Camarero T, Bernal J, et al. Reintervenciones múltiples sobre la válvula mitral: 30 años de experiencia. Rev Esp Cardiol 2009; 62: 929-32. [ Links ]

    11. Alonso-Briales J, Muñoz-García A, Jiménez-Navarro M, et al. Utilización de los dispositivos Amplatzer para el cierre de fugas perivalvulares. Rev Esp Cardiol 2009; 62: 442-6. [ Links ]

    12. Ruiz C, Roubin G, Cohen H, et al. Clinical outcomes in patients undergoing percutaneous closure of periprosthetic paravalvular leaks. J Am Coll Cardiol 2011; 58: 2210-7. [ Links ]

    13. Sorajja P, Cabalka A, Hagler D, Rihal C. Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation. J Am Coll Cardiol 2011; 58: 2218-24. [ Links ]

    14. Bogunovic N, Faber L, Scholtz W, Mellwig K, Horstkotte D, Van Buuren F. Real-time three-dimensional transoesophageal echocardiography during percutaneous transcatheter occlusion of mitral periprosthetic paravalvular leak. Eur J Echocardiogr 2011; 12: E27. [ Links ]

    15. Kim M, Casserly I, Garcia J, Klein A, Salcedo E, Carroll J. Percutaneous transcatheter closure of prosthetic mitral paravalvular leaks. Are we there yet? Am Coll Cardiol Intv 2009; 2: 81-90. [ Links ]

    1. Moutsopoulos HM. Síndrome de Sjögren. En: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL eds. Principios de Medicina Interna. 16ª ed. Mexico: McGraw-Hill Interamericana, 2005, p 2190-3. [ Links ]

    2. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren´s syndrome: a revised version of the European criteria proponed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8. [ Links ]

    3. Manganelli1 P, Fietta1 P, Quaini F. Hematologic manifestations of primary Sjögren's syndrome. Clin Exp Rheumatol 2006; 24: 438-48. [ Links ]

    4. del Brutto, OH. Infecciones micóticas del sistema nervioso central. Rev Neurol 2000; 30: 447-59. [ Links ]

    5. de Fernández MIG, Negroni R, Arechavala A. Absceso tibial causado por histoplasma capsulatum. Medicina (B Aires) 2001; 61: 191-2 [ Links ]

    6. Wheat J, Kauffman C. Pathogenesis and clinical manifestations of disseminated histoplasmosis. En: UpToDate, Waltham, MA: Basow DS (Ed), 2011. [ Links ]

    7. Torres-Rodríguez JM, Segura-Roca G, Coll J. Histoplasmosis en un varón inmunocompetente manifestada 45 años después de la infección. Rev Iberoam Micol 2009; 26: 244-6. [ Links ]

    8. Duncan RA, von Reyn CF, Alliegro GM, Toossi Z, Sugar AM, Levitz SM. Idiopathic CD4 + T-lymphocytopenia: four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med 1993; 328: 393-8. [ Links ]

    9. Schulze-Koops H. Lymphopenia and autoinmune disease, Artritis Research & Therapy 2004; 6:178-80. [ Links ]

    10. Kauffman, CA. Diagnosis of histoplasmosis in immunosuppressed patients. Current Opinion in Infectious Diseases 2008; 21: 421-5. [ Links ]

    11. Vázquez F, Beguelin Y, Schutz N, Mayorga L. Colagenopatía y meningitis aséptica recurrente en una paciente de 88 años. Medicina (B Aires) 2004; 64: 54-6. [ Links ]

    12. Peching G, Kumakawa Z, Galarza C. Histoplasmosis diseminada aguda: enfoque de manifestaciones cutáneas. Folia Dermatol Perú 2004; 15: 172-5. [ Links ]

    13. Cunha VS, Zampese MS, Aquino VR, Cestari TF, Goldani LZ. Mucocutaneus manifestation of disseminated histoplasmosis in patients with acquired inmunodeficiency syndrome: particular aspects in a Latin-American population. Clin Exp Dermatol 2007; 32: 250-5. [ Links ]

    14. Mandl T, Bredberg A, Jacobsson LT, Manthorpe R, Henriksson G: CD4+ T lymphocytopenia- A frequent finding in anti-SSA antibody seropositive patients with primary Sjögren's syndrome. J Rheumatol 2004; 31: 726-8. [ Links ]

    15. Zazzetti F, Rivero MA, Duartes Noe DE, et al. Frequency of systemic manifestations in patients with primary Sjogren's syndrome in Argentina. Reumatol Clin 2010; 6: 299-302. [ Links ]

    1. Remer TG (editor). SERENDIPITY and the Three Princes from the Peregrinaggio of 1557. Norman: University of Oklahoma Press, 1965. [ Links ]

    2. Pasqualini RQ. Houssay y el serendipismo. Medicina (B Aires) 1981; 41: 827-30. [ Links ]

    3. Serendipia. En: http://es.wikipedia.org/wiki/Serendipia; consultado 28/05/2012. [ Links ]

    4. Serendipity. En: http://es.wikipedia.org/wiki/Serendipity; consultado 28/05/2012. [ Links ]

    5. Alonso H. Serendipity en medicina clínica. Medicina (B Aires) 2001; 61: 369-72. [ Links ]

    6. Alonso H. Palabras, palabras, palabras, sin figuras ni conversaciones. Rosario: Corpus Editorial, 2006, p 171-7. [ Links ]

    7. Pasqualini CD. Entretelones del invento de los anticuerpos monoclonales. Medicina (B Aires) 2008; 68: 475-7. [ Links ]

    8. Stekolschik G. El azar y la sagacidad. Exactamente 2012; 49: 10-3. [ Links ]

    9. Pasqualini CD. Quise lo que hice. Autobiografía de una investigadora científica. Buenos Aires: Leviatán, 2007. [ Links ]

    1. Latil M, Rocheteau P, Châtre L, et al. Skeletal muscle stem cells adopt a dormant cell state postmortem and retain regenerative capacity. Nat Commun 2012; Jun 12; 3: 903. En: http://www.nature.com/ncomms/journal/v3/n6/pdf/ncomms1890.pdf; consultado 3/8/12; Press release, I. Pasteur. En: http://www.pasteur.fr/ip/easysite/pasteur/en/press/press-releases/2012/postmortem-stem-cells; consultado 20/8/12. [ Links ]

    2. Vogel G. Cancer Stem Cells Can Fuel Tumor Growth. En: http://www.wired.com/wiredscience/2012/08/cancer-stemcells/; consultado 3/8/12. [ Links ]

    3. Schepers A G, Snippert H J, Stange D E, et al. Lineage Tracing Reveal Lgr5+ Stem Cell Activity in Mouse Intestinal Adenoma. Science, 2012; 337: 730-5. [ Links ]

    4. Zhenyu Tang, Aijun Wang, Falei Yuan, et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nature Communications, June 2012. En: http://www.nature.com/ncomms/journal/v3/n6/full/ncomms1867.html; consultado 3/8/12. [ Links ]

    5. Semeniuk GB. Stem cells en relación a la reparación de lesiones pulmonares. Revista Argentina de Medicina Respiratoria 2005; 1: 1-2. [ Links ]

    6. Pasqualini CD. Reprogramación de fibroblastos humanos a células madre. Nuevo paradigma en medicina regenerativa. Medicina (B Aires) 2008; 68: 181-3. [ Links ]

    7. Pasqualini CD. La guerra contra el cáncer. Medicina (B Aires) 2011; 71: 496-9. [ Links ]

    1. Allison, RS. Disseminated sclerosis in North Wales: an inquiry into its incidence, frequency, distribution and other etiological factors. Brain 1931; 53: 391-430. [ Links ]

    2. Poser, CM. An Atlas of Multiple Sclerosis; In: Multiple sclerosis: epidemiology. 2nd ed. Nashville: Parthenon Publishing Group 1998, p 23-35. [ Links ]

    3. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 182-91. [ Links ]

    4. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22: 117-39. [ Links ]

    5. Rosati G, Aiello I, Pirastru MI, et al. Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. Neuroepidemiology 1996; 15: 10-9. [ Links ]

    6. Cristiano E, Patrucco L, Rojas JI. A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol 2008; 15: 1273-8. [ Links ]

    7. Rosati G. Descriptive epidemiology of multiple sclerosis in Europe in the 1980s: a critical overview. Ann Neurol 1994; 36 Suppl 2: S164-74. [ Links ]

    8. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12. [ Links ]

    9. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097. [ Links ]

    10. Cristiano E, Patrucco L, Rojas JI, et al. Prevalence of multiple sclerosis in Buenos Aires, Argentina using the capture-recapture method. Eur J Neurol 2009; 16:183-7. [ Links ]

    11. Cristiano E, Patrucco L, Giunta D, Videla G, Soriano ER, Rojas JI. Incidence of multiple sclerosis in Buenos Aires: a 16-year health maintenance organization-based study. Eur J Neurol 2010; 17: 479-82. [ Links ]

    12. Melcon MO, Vergara RH, Ceratto R. Prevalencia de Esclerosis Múltiple en Junín, Provincia de Buenos Aires, Argentina. Rev Neurol 1994; 19: 3-8. [ Links ]

    13. Melcon M, Gold L, Carra A, et al. Argentine Patagonia: prevalence and clinical features of multiple sclerosis. Mult Scler 2008; 14: 656-62. [ Links ]

    14. Cristiano E, Patrucco L, Garcea O, et al. Prevalence of multiple sclerosis in Argentina estimated by capture recapture method. J Neurol Sci 1999; 2: A438. [ Links ]

    15. Piedrabuena R, Giobellina R, Alvarez D, V A. High prevalence of multiple sclerosis in the city of Oliva, Cordoba, Argentina. Arq Neuropsiquiatr 2004; 62: 13. [ Links ]

    16. Cristiano E, Patrucco L, Carrá A, et al. Características clínico evolutivas de la esclerosis múltiple en Argentina. Estudio multicéntrico. Neurologia Argentina 1999; 24: 13. [ Links ]

    17. Sandoval G, Fernández Liguori N, Cáceres F, Sica R, Garcea O. Características de inicio en la esclerosis múltiple en recaídas y remisiones. Neurologia Argentina 2000; 25: 36. [ Links ]

    18. Sandoval G, Villa A, Vanotti S, Garcea M, Garcea O. Esclerosis Múltiple dos décadas de experiencia. Neurología Argentina 2004; 29: 16. [ Links ]

    19. Saladino L, Fernández Liguori N. Características clínico demográficas de una población con esclerosis múltiple en un Hospital público de Capital Federal. Neurología Argentina 2006; 31: 46. [ Links ]

    20. Rojas JI, Patrucco L, Riccio P, Cristiano E. Historia natural de la esclerosis múltiple: severidad de la enfermedad en una cohorte de Argentina. Neurologia Argentina 2008; 33: 7. [ Links ]

    21. Rojas JI, Patrucco L, Cristiano E. Historia natural de la esclerois múltiple primaria progresiva en Buenos Aires. Neurologia Argentina 2009; 1: 15. [ Links ]

    22. Vetere S, Muñiz R, Luisi AM, E. Esclerosis múltiple: análisis epidemiológico. Revista Neurológica 1998; 23: 3. [ Links ]

    23. Bardeci C, Cristiano E, Torres D, Serra P. Esclerosis múltiple: Datos epidemiológicos en 150 pacientes. Revista Neurológica Argentina 1994; 19:26. [ Links ]

    24. Caceres FS, Kremenchutzky MFL, Garcea O. Análisis de una población de pacientes con esclerosis múltiple. Revista Neurológica Argentina 1993; 21: 175. [ Links ]

    25. Bardeci C, Patrucco L, Torres D, Cristiano E. Consultorio de esclerosis múltiple, cinco años de experiencia. Revista Neurológica Argentina 1993; 21: 215. [ Links ]

    26. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-78. [ Links ]

    27. Lauer K. Environmental associations with the risk of multiple sclerosis: the contribution of ecological studies. Acta Neurol Scand Suppl 1995;161: 77-88. [ Links ]

    28. Dolinoy DC, Jirtle RL. Environmental epigenomics in human health and disease. Environ Mol Mutagen 2008; 49: 4-8. [ Links ]

    29. Kurtzke JF. MS epidemiology world wide. One view of current status. Acta Neurol Scand Suppl 1995; 161: 23-33. [ Links ]

    30. Kurtzke JF. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol Sci 2000; 21: 383-403. [ Links ]

    31. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-6. [ Links ]

    32. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584-94. [ Links ]

    33. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13:119-46. [ Links ]

    1. Borrell Bentz R. La educación médica de posgrado en Argentina: el desafío de una nueva práctica educativa. 1 ed. Buenos Aires: OPS/OMS, 2005. [ Links ]

    2. Barousse AP. Certificación de profesionales médicos en la especialidad Clínica Médica. Medicina (B Aires) 2002; 62: 609-11. [ Links ]

    3. Accreditation Council for Graduate Medical Education ACGME Program Requirements for Residency Education in Internal Medicine http://www.acgme.org/acWebsite/downloads/RRC_progReq/140_im_07012007.pdf.; consultado julio 2007. [ Links ]

    4. Levine RB, Hebert RS, Wright SM. Resident research and scholarly activity in internal medicine residency training programs. J Gen Intern Med 2005; 20: 155-9. [ Links ]

    5. García GMG. Residencias del equipo de salud. Sistema Nacional de Acreditación de Residencias del Equipo de Salud. Criterios básicos. Integrantes del sistema. Registros, Min. Salud y Medio Ambiente. Dirección Nacional del Boletín Oficial: Buenos Aires, 2006. [ Links ]

    6. Elizondo CM, Giunta DH, González Bernaldo de Quirós F, et al. Residencias de medicina interna en Argentina, 2008. Medicina (B Aires) 2010; 70: 143-50. [ Links ]

    7. Van der Steen JT, Ooms ME, Ader HJ, Ribbe MW, van der Wal G. Withholding antibiotic treatment in pneumonia patients with dementia: a quantitative observational study. Arch Intern Med 2002; 162: 1753-60. [ Links ]

    8. Meyers FJ, Weinberger SE, Fitzgibbons JP, et al. Redesigning residency training in internal medicine: the consensus report of the Alliance for Academic Internal Medicine Education Redesign Task Force. Acad Med 2007; 82: 1211-9. [ Links ]

    9. Fletcher KE, Underwood W 3rd, Davis SQ, et al. Effects of work hour reduction on residents' lives: a systematic review. JAMA, 2005; 294: 1088-100. [ Links ]

    10. Hamann KL, Fancher TL, aint S, Henderson MC. Clinical research during internal medicine residency: a practical guide. Am J Med 2006; 119: 277-83. [ Links ]

    11. Alguire PC, Anderson WA, Albrecht RR, Poland GA. Resident research in internal medicine training programs. Ann Intern Med 1996; 124: 321-8. [ Links ]

    12. Vinci RJ, Bauchner H, Finkelstein J, et al. Research during pediatric residency training: outcome of a senior resident block rotation. Pediatrics 2009; 124: 1126-34. [ Links ]

    13. Kanna B, Deng C, Erickson SN, et al. The research rotation: competency-based structured and novel approach to research training of internal medicine residents. BMC Med Educ 2006; 6: 52. [ Links ]

    14. Rivera JA Levine RB, Wright SM. Completing a scholarly project during residency training. Perspectives of residents who have been successful. J Gen Intern Med 2005; 20: 366-9. [ Links ]

    15. Fuentes NA, Giunta DH, Pazo V, et al. Proyecto institucional para la educación médica continua en investigación clinica. Medicina (B Aires) 2010; 70: 240-6. [ Links ]

    16. Pereiro ND, Elizondo C, Giunta D, Figa S. Clinical Eepidemiologic Research in Internal Medicine Residencies in Argentina. Qualitative Study, in 29Th World Congress of Internal Medicine 2008: Buenos Aires. [ Links ]

    17. González García GM. Residencias del equipo de salud. Sistema Nacional de Acreditación de Residencias del Equipo de Salud. Criterios básicos. Integrantes del sistema. Registros. En: http://www.femeba.org.ar/fundacion/, Min. Salud y M. Ambiente, Dirección Nacional del Boletín Oficial: Buenos Aires, 2006. [ Links ]

    1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907. [ Links ]

    2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636. [ Links ]

    3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. [ Links ]

    4. Bruni L, Díaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99. [ Links ]

    5. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-5. [ Links ]

    6. Arrossi S, Ramos S, Paolino M, Sankaranarayanan R. Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina. Reprod Health Matters 2008; 16: 50-8. [ Links ]

    7. Arrossi S. Proyecto para el mejoramiento del Programa Nacional de Prevención de Cáncer de Cuello Uterino en Argentina. Informe final: Diagnóstico de situación del Programa Nacional y Programas Provinciales. 1 ed. Buenos Aires: Organización Panamericana de la Salud, OPS; 2008. In: http://www.msal.gov.ar/cancer-cervico-uterino/pdf/info-equipos-salud/Diagnostico_Pub64_OPS.pdf (last accessed 14-11-2011). [ Links ]

    8. Bernard HU, Chan SY, Manos MM, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994; 170: 1077-85. [ Links ]

    9. Manos MM, Ting Y, Wright DK, Lewis AJ, Brocker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 1989; 7: 209-14. [ Links ]

    10. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76 (Pt 4): 1057-62. [ Links ]

    11. Ho L, Chan SY, Burk RD, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993; 67: 6413-23. [ Links ]

    12. Picconi MA, Gronda J, Alonio LV, et al. Human Papilloma virus in Quechua women from Jujuy with high frequency of cervical cancer: viral types and HPV-16 variants. Medicina (B Aires) 2002; 62: 209-20. [ Links ]

    13. Tonon SA, Picconi MA, Zinovich JB, et al. Human papillomavirus cervical infection in Guarani Indians from the rainforest of Misiones, Argentina. Int J Infect Dis 2004; 8: 13-9. [ Links ]

    14. Soto-De Leon S, Camargo M, Sanchez R, et al. Distribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. PLoS One 2011; 6: e14705. [ Links ]

    15. Brito EB, Silva ID, Stávale JN, Taromaru E, Menezess RC, Martins SJ. Amerindian women of the Brazilian Amazon and STD. Eur J Gynaecol Oncol 2006; 27: 279-81. [ Links ]

    16. Kightlinger RS, Irvin WP, Archer KJ, et al. Cervical cancer and human papillomavirus in indigenous Guyanese women. Am J Obstet Gynecol 2010; 202: 626. e1-7. [ Links ]

    17. de Sanjosé S, Díaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-9. [ Links ]

    18. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Piñeros M. Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine 2008; 26: L1-15. [ Links ]

    19. Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine 2008; 26: L16-36. [ Links ]

    20. Lippman SA, Sucupira MCA, Jones HE, et al. Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. Int J STD AIDS 2010; 21: 105-9. [ Links ]

    21. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-84. [ Links ]

    22. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43: S5-25, S25. e1-41. [ Links ]

    23. Franceschi S, Rajkumar R, Snijders PJF, et al. Papillomavirus infection in rural women in southern India. Br J Cancer 2005; 92: 601-6. [ Links ]

    24. Muñoz N, Méndez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87. [ Links ]

    25. Tábora N, Bakkers JM, Quint WG, et al. Human papillomavirus infection in Honduran women with normal cytology. Cancer Causes Control 2009; 20: 1663-70. [ Links ]

    26. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco MD, Silini EM. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol 2009; 113: 115-9. [ Links ]

    27. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80. [ Links ]

    28. Bello BD, Spinillo A, Alberizzi P, et al. Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions. J Med Virol 2009; 81: 703-12. [ Links ]

    29. Sichero L, Ferreira S, Trottier H, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120: 1763-8. [ Links ]

    30. Xi LF, Koutsky LA, Hildesheim A, et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev 2007; 16: 4-10. [ Links ]

    31. Sichero L, Villa LL. Epidemiological and functional implications of molecular variants of human papillomavirus. Braz J Med Biol Res 2006; 39: 707-17. [ Links ]

    32. Tonon SA, Basiletti J, Badano I, et al. Human papillomavirus type 16 molecular variants in Guarani Indian women from Misiones, Argentina. Int J Infect Dis 2007; 11: 76-81. [ Links ]

    33. Picconi MA, Alonio LV, García Carrancá A, et al. Molecular variants of human papillomavirus (HPV) types 16 and 18 in adenocarcinomas of the cervix. Medicina (B Aires) 2000; 60: 889-94. [ Links ]

    34. Alencar TR, Cerqueira DM, da Cruz MR, Wyant PS, Ramalho ED, Martins CR. New HPV-16 European and non-European variants in Central Brazil. Virus Genes 2007; 35: 1-4. [ Links ]

    1. Ding EL, Hu FB. Smoking and type 2 diabetes: under recognized risks and disease burden. JAMA 2007; 298: 2675-6. [ Links ]

    2. Mathur RK. Role of diabetes, hypertension, and cigarette smoking on atherosclerosis. J Cardiovasc Dis Res 2010; 1: 64-8. [ Links ]

    3. Alanbaei M, Zubaid M, Al-Mallah MH, et al. Impact of diabetes and smoking epidemic in the Middle East on the presentation with acute coronary syndrome in very young patients. Angiology 2012; 63: 48-54. [ Links ]

    4. Matsubayashi H, Maeda A, Kanemoto H, et al. Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. Pancreas 2011; 40: 974-8. [ Links ]

    5. Zedan H, Hareadei AA, Abd-Elsayed AA, Abdel-Maguid EM. Cigarette smoking, hypertension and diabetes mellitus as risk factors for erectile dysfunction in upper Egypt. East Mediterr Health J 2010; 16: 281-5. [ Links ]

    6. Cho NH, Chan JC, Jang HC, Lim S, Kim HL, Choi SH. Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study. Clin Endocrinol (Oxf) 2009; 71: 679-85. [ Links ]

    7. Fagard RH, Nilsson PM. Smoking and diabetes-the double health hazard! Prim Care Diabetes 2009; 3: 205-9. [ Links ]

    8. Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 108: 1713-26. [ Links ]

    9. Heistein JB, Cook PA. Factors affecting composite graft survival in digital tip amputations. Ann Plast Surg 2003; 50: 299-303. [ Links ]

    10. Mowlavi A, Andrews K, Milner S, Herndon DN, Heggers JP. The effects of hyperglycemia on skin graft survival in the burn patient. Ann Plast Surg 2000; 45: 629-32. [ Links ]

    11. Ramos G, Guastavino MP, Bolgiani A, Prezzavento G. Patiño 0, Benaim F. Hypoalbuminemia in burned patients: an outcome marker that could define evolution periods. Revist Argent Quemad 2000; 15: 23-9. [ Links ]

    12. Vibe P, Pless J. A new method of skin graft adhesion. Scand J Plast Reconstr Surg 1983; 17: 263-4. [ Links ]